

Programme

Tuesday October 5th

14.00 - 18.00 Registration

18.00 - 21.00 Welcome reception

Wednesday October 6th Main Lecture Theatre

9.00 - 9.20 Welcome

Inflammation and Fibrin Regulation

Chair: **Jeremy Thompson (London, UK)**
Jack Gauldie (Hamilton, Canada)

9.20 - 10.00 **S Idell (Tyler, USA)**
Post-translational regulation of the urokinase receptor by mesothelial and mesothelioma cells [1]

10.00 - 10.40 **L Holmdahl (Göteborg, Sweden)**
Proteases in peritoneal tissue repair [2]

10.40 - 11.10 *Coffee*

Chair: **Stephen Idell (Tyler, USA)**
Lena Holmdahl (Göteborg, Sweden)

11.10 - 11.50 **T Kooistra (Rotterdam, Netherlands)**
Peritoneal Fibrinolysis [3]

11.50 - 12.05 **GJ Bellingan, H Cooksley, F Chua, GJ Laurent, SE Mutsaers (London, UK)**
Macrophage adhesion to mesothelial cells during the resolution of acute and chronic peritoneal inflammation [4]

12.05 - 12.20 **TS Wilkinson, AS Williams, U Janssen, U Kunter, J Floege, N Topley (Cardiff, UK)**
The role of interleukin-6 (IL-6) in peritoneal inflammation: Control of neutrophil influx during peritoneal inflammation by a chemokine dependent mechanism [5] **NIA**

12.20 - 12.35 **CM Hoff, KL Inman, D Piscopo, TR Shockley (McGaw Park, USA)**
Mesothelial cells genetically modified to produce IL-10 inhibit macrophage production of proinflammatory cytokines [6]

12.35 - 14.00 *Lunch*

Serosal repair

Chair: **Stephen Albelda (Philadelphia, USA)**
PAX

14.00 - 14.40 **E Hay (Boston, USA)**
Epithelial-mesenchymal transformation [7]

14.40 - 15.20 PJ Margetts, TM Galt, M Kolb, **J Gauldie (Hamilton, Canada)**
The effect of transient overexpression of transforming growth factor beta on the peritoneal membrane [8]

15.20 - 15.35 **W Sendt, G Wolff-Vorbeck, BU Specht, U Schöffel (Freiburg, Germany)**
Co-cultured human mesothelial and endothelial cells as an access for studying the physiology of the peritoneal membrane [9]

15.35 - 16.05 *Tea*

Chair: **Agnes Kane (Providence, USA)**
PAX

16.05 - 16.45 **A Raftery (London, UK)**
Peritoneal repair: the early days [10]

16.45 - 17.00 **S Mutsaers, D Whitaker, JM Papadimitriou (London, UK)**
Mesothelial regeneration is not dependent on subserosal cells [11]

17.00 - 17.15 **T Al-Mishlab, SE Herrick, GJ Laurent, SE Mutsaers (London, UK)**
Phenotypic changes are not demonstrated in submesothelial cells during serosal healing [12] **NIA**

17.15 - 17.30 **AJ Foley - Comer, SE Herrick, T Al-Mishlab, GJ Laurent, SE Mutsaers (London, UK)**
Di-I labelled cultured mesothelial cells are incorporated into regenerating mesothelium: Identification of putative progenitor cells [13] **NIA**

18.30 - 23.00 Cocktail reception, dinner and Monte Carlo evening

Thursday October 7th

Library

Chair:

Philippe Chahinian (New York, USA)
Paul Baas (Amsterdam, Netherlands)

9.00 - 9.40

V Rush (New York, USA)
The IMIG staging system: How relevant is it? [M1]

9.40 - 10.20

J F Early, EJ Earley (New York, USA)
The state of asbestos litigation in 1999 [M2]

10.20 - 10.50

Coffee

10.50 - 11.30

SM Albelda (Philadelphia, USA)
Gene therapy for benign and malignant disorders [M3]

11.30 - 11.45

DH Serman, A Recio, K Molnar-Kimber, K Amin, J Hughes, A Alavi, M Lanuti, LA Litzky, SM Albelda, LR Kaiser (Philadelphia, USA)
Herpes simplex virus thymidine kinase (HSV tk) gene therapy utilizing an E1/E4-deleted adenoviral vector: Preliminary results of a phase I clinical trial for pleural mesothelioma [M4]

11.45 - 12.00

JPC Steele, MT Evans, J Shamash, NH Gower, MD Tischkowitz, RM Rudd (London, UK)
Effective palliation of malignant pleural mesothelioma (MPM): A phase II study of vinorelbine [M5] **NIA**

12.00 - 12.15

C Robinson, M Callow, S Stevenson, BWS Robinson, **R Lake, (Perth, Australia)**
Antigens associated with malignant mesothelioma [M6]

12.15 - 12.30

C Vivo, F Levy, J Fleury-Feith, K Leroy, L Kheuang, I Monnet, D Chopin, MC Jaurand (Créteil, France)
Cell cycle analysis in interferon gamma (IFN) treated human mesothelioma cell lines (HMCLs) [M7] **NIA**

12.30 - 14.00

Lunch

12.30 - 13.30

IMIG Committee Meeting

Chair:

Bruce Robinson (Perth, Australia)
Courtney Broaddus (San Francisco, USA)

14.00 - 14.15

K Dobra, X Sun, A Hjerpe (Stockholm, Sweden)
Differences in gene expression between epithelial and fibrous mesothelioma cells [M8]

14.15 - 14.30

L Mutti, PG Betta, L Strizzi, R Libener, G Tassi, R Puntoni, A Procopio (Vercelli, Italy)

(Simian virus 40 (SV-40) - like DNA sequences, histology and survival in pleural malignant mesothelioma [M9]

14.30 - 15.45

Poster discussion

JG Edwards, J MvLaren, RA Walker, DA Waller, KJ O'Byrne (Leicester, UK)

Evaluation of matrix metalloproteinase activity in malignant mesothelioma and benign pleura [P1]

P Harvey, D Edwards, R Warn (Norwich, UK)

Expression of matrix metalloproteinases in mesothelioma cell lines their regulation by hepatocyte growth factor/scatter factor [P2]

R Foddis, A Vivaldi, G Guglielmi, V Gattini, R Buselli, G Sensales, EM Giancia, A Powers, F Ottenga, A Cristaudo (Pisa, Italy)

Study about SV 40-sequences in paraffin embedded mesothelioma samples [P3]

K Takabe, K Tsuchiya, T Fukuoka, Y Kodaira, Y Shinohara, S Usui, M Inagaki, N Funakoshi, K Suzuki, H Akabane, H Ishiwata, H Miura, K Horita, NINase (Ibaraki, Japan)

SV-40-like DNA sequences in malignant mesothelioma in Japan [P4]

S Orecchia, R Libener, G Gaudino, L Mutti, PG Betta (Alessandria, Italy)

The expression and cellular location of E- and N-cadherins in malignant mesothelioma [P5]

MT Valle, R Libener, F Mignone, PG Betta, G Gaudino, A Procopio, L Strizzi, R Guida, L Mutti (Vercelli, Italy)

Transforming growth factor β (TGF β)- released by PPD-presenting malignant mesothelioma cells (MMC) inhibits IFN γ synthesis by an anti-PPD CD4 T cell clone (TCC) [P6]

K Amin, A Kallarakal, DH Serman, RL Kaiser, DM Jacobowitz, SM Albelda (Philadelphia, USA)

The regulation of the mouse calretinin promoter in mesothelioma cells [P7]

V Ascoli, C Carnovale Scalzo, F Nardi, D Falzetti, C Mecucci (Rome, Italy)

Familial aggregation of malignant mesothelioma: Five affected in one family with cancer history. Is there a genetic predisposition? [P8]

CM Hoff, D Piscopo, KL Inman, TR Shockley (McGaw Park, USA)

Adenovirus mediated gene transfer to the peritoneal cavity [P9]

and

persons

Y Inoue, T Nakano, M Miyake, A Tonomura, S Iida, N Togawa, T Hada (**Hyogo, Japan**)
Soluble CD44 and its immuno-histochemical expression in patients with malignant pleural mesothelioma [P10]

R Hübner, E Van Marck (**Wilrijk, Belgium**)
Detection of polyomavirus DNA in malignant pleural mesothelioma from Belgian patients [P11]

JPJJ Hegmans, H Kuipers, K Radosevic, S Burgers, HC Hoogsteden, J-B Prins (**Rotterdam, Netherlands**)
Isolation of antibodies from a semi-synthetic phage-antibody-display library to mesothelioma specific cell surface molecules [P12]

FM Kogan, SA Berzin, NA Tomilova (**Ekaterinburg, Russian Federation**)
Mesothelioma of pleura and chrysotile asbestos exposure [P13]

JG Edwards, JN Leverment, TJ Spyt, DA Waller, KJ O'Byrne (**Leicester, UK**)
Ten years of malignant mesothelioma in Leicester: Prognostic factors [P14]

(Leicester,

JG Edwards, G Cox, RA Walker, DA Waller, KJ O'Byrne (**UK**)
Increased chalkley microvessel counts are related to platelet count and convey poor prognosis in malignant mesothelioma [P15]

G Hillerdal, M Metintas, E Rasmussen, S Metintas (**Stockholm, Sweden**)
Erionite exposure: High mesothelioma rate despite lack of benign pleural lesions [P16]

N Togawa, T Nakano, Y Inoue, S Iida, T Atsusi, M Miyake, K Hada (**Hyogo, Japan**)
Soluble FAS (sFas) and FAS ligand (sFasL) in patients with malignant pleural mesothelioma [P17]

T Ollikainen, A Knuutila, S Suhonen, A Jekunen, K Mattson, K Linnainmaa (**Helsinki, Finland**)
In *vitro* sensitivity of malignant mesothelioma cell lines to four new chemotherapeutic agents [P18]

A Knuutila, T Ollikainen, A Jekunen, M Halme, K Linnainmaa, K Mattson (**Helsinki, Finland**)
Docetaxel and irinotecan (CPT-11) for malignant mesothelioma [P19]

E Kettunen, W El-Rifai, A-M Nissinen, T Ollikainen, M Taavitsainen, K Linnainmaa, **S Knuutila (Helsinki, Finland)**

cDNA array study of gene expression profiles in malignant mesothelioma cell lines [P20]

15.45 - 16.05

Tea

Chair:

Marie-Claude Jaurand (Créteil, France)
Anders Hjerpe (Stockholm, Sweden)

16.05 - 16.20

VC Broaddus, W Liu, GD Rosen (San Francisco, USA)
TNF-related apoptosis-inducing ligand can induce apoptosis in mesothelioma cell lines [M10]

16.20 - 16.35

SP Faux, CE Houghton, A Hubbard, G Patrick (Leicester, UK)
Expression of epidermal growth factor-receptor (EGF-R) in rat pleural mesothelial cells correlates with fibre carcinogenicity [M11]

16.25 - 16.50

E Kagan, S Tanaka, N Choe, A Iwagaki, J Zhang, DR Hemenway (Burlington, USA)
Role of MCP-1 and mesothelial-leukocyte adhesion an asbestos-induced pleural injury [M12]

16.50 - 17.05

JG Edwards, SP Faux, RA Walker, DA Waller, KJ O'Byrne (Leicester, UK)
Cyclo-oxygenase-2 expression in malignant mesothelioma (MM) [M13]

17.05 - 17.20

VM Williams, NH de Klerk, KD Wolanski, D Whitaker, KB Shilkin, AW Musk (Perth, Australia)
Retained pulmonary mineral fibre profile and risk of malignant mesothelioma in Western Australia [M14]

17.20 - 17.35

B Nisman, J Lafair, N Heshing, O Lyass, C Reinus, T Peretz, V Barak (Jerusalem, Israel)
Serum tumor markers in malignant pleural mesothelioma [M15]

18.45

Bus departs Stoke Rochford Hall for conference banquet

19.30 - 23.15

Conference banquet (The Sheriff's Lodge)

23.15

Bus returns to Stoke Rochford Hall

Friday October 8th

Main conference Hall

Chair:

Julian Peto (Belmont, UK)
Bruce Case (Montreal, Canada)

9.15 - 9.55

J Peto (Belmont, UK)
The European mesothelioma epidemic [M16]

9.55 - 10.10

J Leigh (Sydney, Australia)
Malignant mesothelioma in Australia (1945-1999) [M17]

10.10 - 10.25

BW Case, V Roggli, A Churg, M Camus, J Siemiatycki (Montreal, Canada)
Pathology validation and asbestos exposure for female pleural peritoneal malignancy in Quebec, Canada [M18]

10.25 - 10.45

Coffee

Chair:

Marjan Versnel (Rotterdam, Netherlands)
Steven Mutsaers (London, UK)

10.45 - 11.25

M Dyer (Sutton, UK)
Bcl10 in malignancy [M19]

11.25 - 11.40

K Takabe, K Tsuchiya, T Fukuoka, Y Kodaira, Y Shinohara, S Usui, M Inagaki, N Funakoshi, K Suzuki, H Akabane, H Ishiwata, H Miura, K Horita, N Inase (Ibaraki, Japan)
Deletion and hypermethylation of the tumor suppressor gene P16/CDKN2 in malignant mesothelioma [M20]

11.40 - 11.55

CA Vaslet, NJ Messier, AB Kane (Providence, USA)
Inactivation of $p16^{INK4a}$, $p15^{INK4b}$ and $p19^{ARF}$ in murine mesothelioma cell lines [M21]

11.55 - 12.35

A Berns (Amsterdam, Netherlands)
The design of specific mouse tumour models using conditional knock-out strategies [M22]

12.35 - 12.45

Committee Meeting Announcements

12.45 - 14.00

Lunch

Chair:

Per-Fredrik Eckhold (Fredrikstad, Norway)
Daniel Sterman (Philadelphia, USA)

14.00 - 14.40

BWS Robinson (Perth, Australia)
New therapies for mesothelioma –what is the best approach? [M24]

14.40 - 14.55

AP Chahinian, H Gluck (New York, USA)

Human mesothelioma xenografts as a model for chemotherapy:
From bench to clinic [M25]

14.55 - 15.10

T Nakano, Y Inoue, A Tonomura, N Togawa, S Iida, M Miyake, N Togawa, T Hada (**Hyogo, Japan**)
Irinotecan(CPT-11) and Doxorubicin(ADR) in the treatment of patients with malignant pleural mesothelioma: A pilot clinical trial [M26]

15.10 - 15.25

phase-II

G Hillerdal, K Mattson, H Riska, S Högberg, O Brodin, H Strander (**Stockholm, Sweden**)
Treatment of malignant pleural mesothelioma with high dose methotrexate and alfa + gamma-interferons. A Scandinavian study [M27]

15.25 - 15.40

study

B Castagneto, M Botta, G Grecchi, D Grosso, M Merlano, C Zanon, S Zai, A Mussa (**Monferrato, Italy**)
Thoracic stop-flow in pleural mesothelioma: A dose-finding [M28]

15.40 - 15.55

JG Edwards, A Rengarajan, DA Waller (**Leicester, UK**)
A “one-stop” protocol of palliative debulking surgery for malignant mesothelioma gives lasting symptom relief [M29]

15.55 - 16.05

Closing remarks

16.05 - 16.35

Tea